This presentation will provide a preview of key insights from Antibodies to Watch in 2027, including a review of antibody therapeutics first approved in 2026, those currently under regulatory review, and a projection of candidates likely to enter regulatory review by the end of 2027. The talk will also feature a focused analysis of emerging trends shaping the antibody therapeutics landscape, offering a data-driven perspective on innovation and pipeline evolution.

Multibodies introduce a new paradigm for multispecific biologics: a single Fab arm engineered to recognize two distinct antigens, enabling the full repertoire of bispecific functionality without requiring two different Fabs. This fundamentally expands the design space for multispecific antibodies unlocking novel binding topologies, programmable cooperativity, and architectures that can be simpler, more modular, and more manufacturable. The talk will outline how dual target single Fab recognition can multiply what is possible in therapeutic multispecific design.

Carcinoembryonic antigen adhesion molecule 5 (CEACAM5) is overexpressed in a subset of patients with colorectal carcinomas, mucinous carcinomas of the ovary and breast, and small-cell lung carcinomas, with minimal expression in normal tissue. We have developed affibody molecules that specifically target CEACAM5-overexpressing tumors and loaded them with lutetium-177. Preclinical studies in mice showed that the constructs can be used to efficiently treat CEACAM5-overexpressing pancreatic tumors with minimal side effects.